«Vogliatemi bene»: lettere di Matilde Serao a Gabriele d’Annunzio

L’esperienza di scrittura di Adele Cambria si è legata al femminismo italiano a partire dalla partecipazione al gruppo romano di Rivolta femminile nel 1970. "Dopo Didone" uscì nel 1973, anno in cui dirigeva «EFFE»; farà parte della redazione di «Quotidiano donna» (1981) e quindi di «Minerva: l’altra metà dell’informazione» (dal 1986) e «Noi Donne» (anni ’80-’90). Questo contributo intende evidenziare la pienezza del suo pensiero nel segno di un giornalismo d’impegno.Adele Cambria’s experience of writing was connected to Italian Feminist Movement thanks to her participation to Rivolta femminile in 1970. "Dopo Didone" was published in 1973, while she was «EFFE»’s editor; then she took part in the editorial board of «Quotidiano donna» (1981) and later in that of «Minerva: l’altra metà dell’informazione» (from 1986) and «Noi Donne» (80s and 90s). This contribution aims to highlight the fullness of her thought in her dedicated work

Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

BackgroundTocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients.MethodsA multicenter, single-arm, hypothesis-driven trial was planned, according to a phase 2 design, to study the effect of tocilizumab on lethality rates at 14 and 30 days (co-primary endpoints, a priori expected rates being 20 and 35%, respectively). A further prospective cohort of patients, consecutively enrolled after the first cohort was accomplished, was used as a secondary validation dataset. The two cohorts were evaluated jointly in an exploratory multivariable logistic regression model to assess prognostic variables on survival.ResultsIn the primary intention-to-treat (ITT) phase 2 population, 180/301 (59.8%) subjects received tocilizumab, and 67 deaths were observed overall. Lethality rates were equal to 18.4% (97.5% CI: 13.6-24.0, P=0.52) and 22.4% (97.5% CI: 17.2-28.3, P<0.001) at 14 and 30 days, respectively. Lethality rates were lower in the validation dataset, that included 920 patients. No signal of specific drug toxicity was reported. In the exploratory multivariable logistic regression analysis, older age and lower PaO2/FiO2 ratio negatively affected survival, while the concurrent use of steroids was associated with greater survival. A statistically significant interaction was found between tocilizumab and respiratory support, suggesting that tocilizumab might be more effective in patients not requiring mechanical respiratory support at baseline.ConclusionsTocilizumab reduced lethality rate at 30 days compared with null hypothesis, without significant toxicity. Possibly, this effect could be limited to patients not requiring mechanical respiratory support at baseline.Registration EudraCT (2020-001110-38); clinicaltrials.gov (NCT04317092)